Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Picking up the Pacing in Obesity: Medtronic acquires Transneuronix

This article was originally published in Start Up

Executive Summary

Medtronic soon will be able to offer a less invasive and safer surgical alternative to gastric bypass surgery, now that it has acquired Transneuronix for $260 million. Transneuronix has developed a gastric pacing device known as Transcend, which stimulates the stomach, and it appears to affect multiple mechanisms in obesity. The device has been approved in Europe, and has been implanted in more than 700 patients worldwide. In the US, Transneuronix has completed enrollment for its pivotal clinical trial.

You may also be interested in...



Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD

Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.

New Data Highlights Benefits, Risks of Obesity Surgery

Obesity has become an epidemic, with 30% of the U.S. population obese and an additional 35% overweight, including children and adolescents. Bariatric surgical procedures have skyrocketed in recent years, with hospital costs exceeding $1.2 billion, and good success rates. However, for certain groups, such as patients over 65, the risks of bariatric surgery may outweigh the benefits. Much needs to be done to address this troubling and growing public health problem.

Neurostimulation Market Expanding

According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel